CytomX to Present at the Jefferies 2017 Global Healthcare Conference
May 25 2017 - 8:00AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical
company developing investigational Probody™ therapeutics for the
treatment of cancer, will present at the Jefferies 2017 Global
Healthcare Conference. Sean McCarthy, D.Phil., president and chief
executive officer will deliver a corporate overview on June 7,
2017, at 3:00 p.m. ET.
A live audio webcast of the presentation will be available
through the Investors and News section of CytomX's website. An
archived replay will be available for 90 days following the
event.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company
pioneering a novel class of investigational antibody therapeutics
based on its Probody technology platform. The Company uses its
platform to create proprietary cancer immunotherapies against
clinically-validated targets, such as PD-L1, and develop
first-in-class cancer therapeutics against difficult-to-drug
targets, such as CD166. Probody therapeutics are designed to take
advantage of unique conditions in the tumor microenvironment to
enhance the tumor-targeting features of an antibody and reduce drug
activity in healthy tissues. The Company’s lead program,
CX-072, a wholly-owned PD-L1-targeting Probody therapeutic, is
being evaluated in a Phase 1/2 study. CX-072 is part of PROCLAIM
(Probody Clinical
Assessment In
Man), an international umbrella clinical trial
program that provides clinical trial sites with access to the
Company’s novel therapies under one central protocol. The trial
initiation for CX-2009, a first-in-class Probody drug conjugate
targeting the highly expressed tumor antigen, CD166, is expected
mid-2017. In addition to its proprietary programs, CytomX is
collaborating with strategic partners, including AbbVie,
Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer
Center and ImmunoGen, Inc. For more information, visit
www.cytomx.com or follow us on Twitter.
Media Contact:
Canale Communications
Ian Stone
ian@canalecomm.com
619-849-5388
Investor Contact:
Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Mar 2024 to Apr 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
From Apr 2023 to Apr 2024